<DOC>
	<DOCNO>NCT01203722</DOCNO>
	<brief_summary>If transplantation use mismatch unrelated donor non-first-degree relative could perform acceptable toxicity profile , important unmet need would serve . Towards goal , current study extend platform nonmyeloablative , partially HLA-mismatched BMT use donor , investigate several postgrafting immunosuppression regimen incorporate high-dose Cy . Of central interest incorporation sirolimus postgrafting immunosuppression regimen . The primary goal identify transplant regimen associate acceptable rate severe acute GVHD NRM Day 100 .</brief_summary>
	<brief_title>Reduced Intensity , Partially HLA Mismatched BMT Treat Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patient 1 . Patient age 0.575 year 2 . Absence suitable relate unrelated bone marrow donor molecularly match HLAA , B , Cw , DRB1 , DQB1 . 3 . Absence suitable partially HLAmismatched ( haploidentical ) , firstdegree relate donor . 4 . Eligible diagnosis : 1 . Relapsed refractory acute leukemia second subsequent remission , remission define &lt; 5 % bone marrow blast morphologically 2 . Poorrisk acute leukemia first remission , remission define &lt; 5 % bone marrow blast morphologically : AML least one following : AML arise MDS myeloproliferative disorder , secondary AML Presence Flt3 internal tandem duplication Poorrisk cytogenetics : Complex karyotype [ &gt; 3 abnormality ] , inv ( 3 ) , ( 3 ; 3 ) , ( 6 ; 9 ) , MLL rearrangement exception ( 9 ; 11 ) , abnormalities chromosome 5 7 Primary refractory disease ALL ( leukemia and/or lymphoma ) least one following : Adverse cytogenetics ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL rearrangement Clear evidence hypodiploidy Primary refractory disease Biphenotypic leukemia 3 . MDS least one follow poorrisk feature : Poorrisk cytogenetics ( 7/7q minus complex cytogenetics ) IPSS score INT2 great Treatmentrelated MDS MDS diagnose age 21 year Progression lack response standard DNAmethyltransferase inhibitor therapy Lifethreatening cytopenia , include generally require great weekly transfusion 4 . Interferon imatinibrefractory CML first chronic phase , nonblast crisis CML beyond first chronic phase . 5 . Philadelphia chromosome negative myeloproliferative disease . 6 . Chronic myelomonocytic leukemia . 7 . Juvenile myelomonocytic leukemia . 8 . Lowgrade nonHodgkin lymphoma ( include SLL CLL ) plasma cell neoplasm progress least two prior therapy ( exclude single agent rituximab single agent steroid ) , case lymphoma undergone histologic conversion 9 . Poorrisk CLL SLL 10 . Aggressive nonHodgkin lymphoma follow , provide stable disease well last therapy : NK NKT cell lymphoma , hepatosplenic Tcell lymphoma , subcutaneous panniculitic Tcell lymphoma Hodgkin aggressive non Hodgkin lymphoma fail least one multiagent regimen , patient either ineligible autologous BMT autologous BMT recommend . Eligible subtypes aggressive nonHodgkin lymphoma include : mantle cell lymphoma follicular grade 3 lymphoma diffuse large Bcell lymphoma subtypes , exclude primary CNS lymphoma primary mediastinal large Bcell lymphoma large Bcell lymphoma , unspecified anaplastic large cell lymphoma , exclude skinonly disease peripheral Tcell lymphoma , include angioimmunoblastic Tcell lymphoma Burkitt 's lymphoma atypical Burkitt 's lymphoma ( highgrade Bcell lymphoma , unclassifiable , feature intermediate diffuse large Bcell lymphoma Burkitt 's ) , complete remission 5 . Patients CLL , SLL , prolymphocytic leukemia must &lt; 20 % bone marrow involvement malignancy ( low risk graft rejection ) . 6 . One following , order low risk graft rejection : Cytotoxic chemotherapy , adequate course 5azacitidine decitabine , alemtuzumab within 3 month prior start condition ; Previous BMT within 6 month prior start condition . NOTE : Patients receive treatment outside window may eligible deemed sufficient reduce graft rejection risk ; decide casebycase basis PI coPI . 7 . Any previous BMT must occur least 3 month prior start condition . 8 . Adequate endorgan function . 9 . ECOG performance status &lt; 2 Karnofsky Lansky score &gt; 60 Patient 1 . Not pregnant breastfeeding . 2 . HIV positive . 3 . No uncontrolled bacterial , viral , fungal infection . 4 . No previous allogeneic BMT ( syngeneic BMT permissible ) . 5 . Active extramedullary leukemia know active CNS involvement malignancy . Such disease treat remission permit . Donor 1 . Potential donor consist : Unrelated donor Seconddegree relative First cousins 2 . The donor recipient must identical least 5 HLA allele base high resolution type HLAA , B , Cw , DRB1 , DQB1 , least one allele match HLA class I gene ( HLAA , B , Cw ) least one allele match class II gene ( HLADRB1 DQB1 ) . 3 . Meets institutional selection criterion medically fit donate . 4 . Lack recipient antidonor HLA antibody . Note : In instance , low level , noncytotoxic HLA specific antibody may permissible find level well detectable flow cytometry . This decide casebycase basis PI one immunogenetics director . Pheresis reduce antiHLA antibody permissible ; however eligibility proceed transplant regimen would contingent upon result . Donor 1 . Donor must HLA identical recipient . 2 . Has donate blood product recipient .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Reduced intensity</keyword>
	<keyword>partially HLA mismatch allogeneic BMT</keyword>
	<keyword>Acute leukemia</keyword>
	<keyword>Chronic leukemia</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>Lymphomas</keyword>
	<keyword>Unrelated non-first-degree related donor</keyword>
</DOC>